Precision Optics (POCI) Competitors $4.80 -0.05 (-1.03%) As of 06/12/2025 03:45 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock POCI vs. LUCD, PDEX, LUNG, ZJYL, KRMD, OBIO, INFU, ICAD, MBOT, and GUTSShould you be buying Precision Optics stock or one of its competitors? The main competitors of Precision Optics include Lucid Diagnostics (LUCD), Pro-Dex (PDEX), Pulmonx (LUNG), Jin Medical International (ZJYL), KORU Medical Systems (KRMD), Orchestra BioMed (OBIO), InfuSystem (INFU), iCAD (ICAD), Microbot Medical (MBOT), and Fractyl Health (GUTS). These companies are all part of the "medical equipment" industry. Precision Optics vs. Its Competitors Lucid Diagnostics Pro-Dex Pulmonx Jin Medical International KORU Medical Systems Orchestra BioMed InfuSystem iCAD Microbot Medical Fractyl Health Precision Optics (NASDAQ:POCI) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings. Does the media prefer POCI or LUCD? In the previous week, Lucid Diagnostics had 3 more articles in the media than Precision Optics. MarketBeat recorded 5 mentions for Lucid Diagnostics and 2 mentions for Precision Optics. Lucid Diagnostics' average media sentiment score of 1.11 beat Precision Optics' score of 0.43 indicating that Lucid Diagnostics is being referred to more favorably in the news media. Company Overall Sentiment Precision Optics Neutral Lucid Diagnostics Positive Which has higher valuation and earnings, POCI or LUCD? Precision Optics has higher revenue and earnings than Lucid Diagnostics. Precision Optics is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecision Optics$17.63M2.09-$2.95M-$0.89-5.39Lucid Diagnostics$4.17M33.96-$52.67M-$1.34-0.98 Which has more volatility & risk, POCI or LUCD? Precision Optics has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Do institutionals & insiders believe in POCI or LUCD? 13.7% of Precision Optics shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 16.3% of Precision Optics shares are owned by insiders. Comparatively, 6.8% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community favor POCI or LUCD? Lucid Diagnostics received 43 more outperform votes than Precision Optics when rated by MarketBeat users. Likewise, 69.35% of users gave Lucid Diagnostics an outperform vote while only 0.00% of users gave Precision Optics an outperform vote. CompanyUnderperformOutperformPrecision OpticsOutperform VotesNo VotesUnderperform Votes2100.00% Lucid DiagnosticsOutperform Votes4369.35% Underperform Votes1930.65% Is POCI or LUCD more profitable? Precision Optics has a net margin of -21.46% compared to Lucid Diagnostics' net margin of -1,069.87%. Lucid Diagnostics' return on equity of 0.00% beat Precision Optics' return on equity.Company Net Margins Return on Equity Return on Assets Precision Optics-21.46% -39.17% -22.93% Lucid Diagnostics -1,069.87%N/A -123.54% Do analysts prefer POCI or LUCD? Lucid Diagnostics has a consensus price target of $3.55, suggesting a potential upside of 170.99%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Precision Optics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision Optics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lucid Diagnostics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryLucid Diagnostics beats Precision Optics on 13 of the 19 factors compared between the two stocks. Get Precision Optics News Delivered to You Automatically Sign up to receive the latest news and ratings for POCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding POCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart POCI vs. The Competition Export to ExcelMetricPrecision OpticsElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.80M$3.31B$5.61B$8.62BDividend YieldN/A1.75%5.28%4.17%P/E Ratio-7.5018.7727.1819.96Price / Sales2.09203.96412.23157.63Price / CashN/A44.0938.2534.64Price / Book3.223.887.064.69Net Income-$2.95M$94.03M$3.23B$248.14M7 Day Performance1.27%8.84%0.80%0.95%1 Month Performance4.80%18.26%9.71%5.74%1 Year Performance-20.98%38.27%32.11%14.73% Precision Optics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)POCIPrecision Optics0.2963 of 5 stars$4.80-1.0%N/A-22.3%$36.80M$17.63M-7.5080Short Interest ↑High Trading VolumeLUCDLucid Diagnostics3.5585 of 5 stars$1.25-10.4%$3.50+181.1%+74.9%$134.70M$4.17M-1.0970Short Interest ↓Gap DownHigh Trading VolumePDEXPro-Dex3.1859 of 5 stars$39.24-2.0%$56.00+42.7%+107.7%$127.96M$64.12M19.52140LUNGPulmonx3.5903 of 5 stars$3.13-7.9%$11.59+270.4%-53.8%$126.01M$87.47M-2.17250Positive NewsZJYLJin Medical InternationalN/A$0.80+6.5%N/A-73.7%$125.24M$23.50M0.00245Short Interest ↓Gap UpKRMDKORU Medical Systems3.3534 of 5 stars$2.79+3.3%$4.50+61.3%+36.2%$124.58M$35.08M-11.1680OBIOOrchestra BioMed3.0746 of 5 stars$3.16+10.9%$14.20+349.4%-60.2%$121.07M$2.89M-1.964INFUInfuSystem2.4277 of 5 stars$5.68-1.7%$13.00+128.9%N/A$119.37M$137.58M94.68410Positive NewsShort Interest ↑ICADiCAD1.063 of 5 stars$3.88+1.0%N/A+144.2%$106.59M$19.53M-29.85140Positive NewsShort Interest ↓MBOTMicrobot Medical2.1526 of 5 stars$2.67+5.1%$9.00+237.1%+127.5%$97.13MN/A-3.3420News CoverageAnalyst RevisionGap DownGUTSFractyl Health2.4173 of 5 stars$1.90flat$11.00+478.9%-64.4%$93.06M$60K-0.16102Positive News Related Companies and Tools Related Companies LUCD Alternatives PDEX Alternatives LUNG Alternatives ZJYL Alternatives KRMD Alternatives OBIO Alternatives INFU Alternatives ICAD Alternatives MBOT Alternatives GUTS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:POCI) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision Optics Co., Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision Optics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
